Given the high prevalence of MVP in the general population, a true association with SCA risk has been controversial.
Dabigatran etexilate, a direct thrombin inhibitor, is one of a new class of oral anticoagulants that was recently demonstrated in a Phase 3 trial to be effective for the prevention of stroke or systemic embolism (SSE) in patients with atrial fibrillation (AF).
Heart failure (HF) is associated with a high mortality rate, debilitating symptoms, impaired quality of life, and major financial costs.
The relationship between patients' prognosis and age in decisions regarding implantable cardioverter-defibrillator (ICD) therapy in the primary prevention of sudden death in heart failure patients is poorly understood and not addressed in randomized device trials. Thus, Dewland and colleagues created a survey that was sent to 3000 randomly selected primary care physicians and general cardiologists nationwide.
